Risk of hospitalization for heart failure in patients with hyperkalemia treated with sodium zirconium cyclosilicate versus patiromer.
Zhuo M, Kim SC, Patorno E, Paik JM.
J Card Fail. 2022 Apr 22. PMID: 35470055
Instructors
Seoyoung C. Kim
Other Positions
Associate Professor of Medicine
Medicine-Brigham and Women's Hospital
Harvard Medical School
Links
Overview
Seoyoung C. Kim, M.D, Sc.D, M.S.C.E, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. She is the Director of the Program in Rheumatologic, Immunologic, and Musculoskeletal PharmacoEpidemiology (PRIME).
She is board-certified in Rheumatology, and co-appointed in the Division of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital. Her research focuses on comparative safety and effectiveness of medications for the rheumatic diseases as well as health services/outcome research in Rheumatology.
Dr. Kim is an Associate Editor for Arthritis Care & Research and ACR Open Rheumatology and has served on a number of Committees for the American College of Rheumatology and the International Society for Pharmacoepidemiology.
BWH DOM Early Career Mentoring Award
Brigham and Women's Hospital
Harvard Catalyst Clinical Research Center Batch Sample Analysis and Assay Validation Award
Harvard Catalyst
Chair's Research Award
Brigham and Women's Hospital, DOM
Henry Kunkel Early Career Investigator Award
American College of Rheumatology
Bibliography
Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Schneeweiss S, Kim SC.
Gut. 2022 Apr 06. PMID: 35387877
Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.
Desai RJ, Varma VR, Gerhard T, Segal J, Mahesri M, Chin K, Horton DB, Kim SC, Schneeweiss S, Thambisetty M.
JAMA Netw Open. 2022 Apr 01. 5(4):e226567. PMID: 35394510
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM.
Cardiovasc Diabetol. 2022 Mar 23. 21(1):47. PMID: 35321742
Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries.
Hawley CE, Lauffenburger JC, Paik JM, Wexler DJ, Kim SC, Patorno E.
Diabetes Care. 2022 03 01. 45(3):604-613. PMID: 35043165
Trends in pharmacologic treatment of chronic idiopathic urticaria from 2016 to 2020.
Li L, Landon JE, Kim SC.
Ann Allergy Asthma Immunol. 2022 May. 128(5):602-603. PMID: 35227905
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ.
Ann Rheum Dis. 2022 Jan 13. PMID: 35027405
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
Patorno E, Htoo PT, Everett BM, Kim SC.
Ann Intern Med. 2022 01. 175(1):W4. PMID: 35038405
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
Patorno E, Htoo PT, Glynn RJ, Schneeweiss S, Wexler DJ, Pawar A, Bessette LG, Chin K, Everett BM, Kim SC.
Ann Intern Med. 2022 01. 175(1):W4-W5. PMID: 35038404
Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.
Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC.
Rheumatology (Oxford). 2021 12 24. 61(1):121-130. PMID: 33752237